2024
Nuclear Imaging of Bispecific Antibodies on the Rise
Roohani B, Mendez A, Dangarwala M, Katz S, Marquez-Nostra B. Nuclear Imaging of Bispecific Antibodies on the Rise. Journal Of Nuclear Medicine 2024, 65: 1512-1517. PMID: 39266295, PMCID: PMC11448611, DOI: 10.2967/jnumed.123.267215.Peer-Reviewed Original Research
2022
Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer
Li Z, Aboian MS, Zhu X, Marquez-Nostra B. Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer. Cancers 2022, 14: 2103. PMID: 35565232, PMCID: PMC9101155, DOI: 10.3390/cancers14092103.Peer-Reviewed Original ResearchPositron emission tomographyBreast cancerMolecular profilingTherapeutic targetSingle photon emission tomography (SPECT) imagingSelection of patientsNuclear imaging agentCustomization of therapyPrecision medicineImaging agentEmission Tomography ImagingMetastatic diseaseClinical evaluationClinical studiesClinical practiceClinical decisionEmission tomographyClinical researchStudy designCancerTomography imagingTherapyDifferent receptorsNoninvasive imagingSPECT agent
2018
Targeting HER2 in Nuclear Medicine for Imaging and Therapy
Massicano AVF, Marquez-Nostra BV, Lapi SE. Targeting HER2 in Nuclear Medicine for Imaging and Therapy. Molecular Imaging 2018, 17: 1536012117745386. PMID: 29357745, PMCID: PMC5784567, DOI: 10.1177/1536012117745386.BooksConceptsHuman epidermal growth factor 2HER2 expressionHER2 statusEpidermal growth factor 2Treatment of patientsHER2-positive cancersWhole-body assessmentStandard diagnostic techniquesMetastatic settingGrowth factor 2Breast cancerClinical studiesNuclear medicineTumor fociInvasive biopsyAlternative treatmentTime of analysisSmall sample sizeTherapyNuclear imagingBiopsyPatientsFactor 2TumorsCancer